Full-Time
Associate Director
Scientific Software Product
Confirmed live in the last 24 hours
BigHat Biosciences
51-200 employees
Develops antibody therapies using machine learning
Senior
San Mateo, CA, USA
- Successfully delivered a software product to end-users, preferably in a scientific context and to scientists/researchers
- Experience working with a software engineering team
- Experience working with customers/stakeholders to understand requirements
- Scientists in a therapeutic or biological sciences context
- Experience hiring, managing and mentoring product owners
- Excellent problem-solver and critical thinker, capable of addressing challenges creatively and efficiently
- Possesses strong written and verbal communication skills, enabling you to explain technical details to a non-technical audience and collaborate effectively with your team.
- Passionate about technology and innovation, constantly seeking to learn and improve your skills.
- Figma or similar prototyping tools
- Diagramming solution for workflows (Miro, etc)
- JIRA or similar task tracker or roadmapping tool
- Software development experience, especially front-end
- Voice of the customer, bridge to engineering
- Meet with every member of the internal science team
- Translate solution requirements into concrete feature requests
- Prioritize and assess impact
- Rank and order the problems by value to the business
- Understand trade-offs in science needs and engineering timelines
- Lead and collaborate with customers/engineers to identify/validate solutions
- Deliver
- Own the roll-out and adoption of new features
- Own the metrics tracking new feature adoption/use/stability/performance
- Own follow through with engineers and follow-up with stakeholders
- Roadmap and direction: scientific needs translated into biweekly, quarterly, annual product plan
- Product lifecycle: Determine how the product is doing. Track current usage, stability, performance.
- Team and org: Determine hiring needs and skills/background to prioritize.
BigHat Biosciences focuses on developing antibody therapies using machine learning and synthetic biology. Their main product is the Milliner platform, which integrates a wet lab with advanced machine learning to streamline the discovery and engineering of antibodies. This platform enables the rapid synthesis, purification, and characterization of numerous recombinant antibodies each week, allowing for quicker development of effective treatments for challenging diseases like infections and cancers. Unlike many competitors, BigHat emphasizes a balance between high performance and a supportive work environment. The company's goal is to create safer and more effective therapies for patients while maintaining a family-friendly culture.
Company Stage
Series B
Total Funding
$99.4M
Headquarters
San Carlos, California
Founded
2019
6 month growth
↑ 17%1 year growth
↑ 32%2 year growth
↑ 112%
Simplify's Take
What believers are saying
- BigHat's recent $75 million Series B funding round, led by prominent investors, provides substantial financial backing for aggressive expansion and product development.
- The company's emphasis on work-life balance and a family-friendly culture makes it an attractive workplace in the high-pressure biotech industry.
- Collaborations with major pharmaceutical companies like Merck and Johnson & Johnson offer significant opportunities for career growth and exposure to cutting-edge research.
What critics are saying
- The competitive biotech landscape requires continuous innovation to maintain a leading position, which can be resource-intensive.
- Dependence on strategic partnerships for growth could pose risks if these collaborations do not yield expected results.
What makes BigHat Biosciences unique
- BigHat Biosciences leverages its proprietary Milliner platform, which integrates synthetic biology and machine learning, to accelerate the discovery and engineering of high-quality antibodies, setting it apart from traditional biotech approaches.
- The company's focus on difficult-to-treat diseases, such as certain infections and cancers, positions it uniquely in the biotech market, targeting areas with significant unmet medical needs.
- Strategic collaborations with industry giants like Johnson & Johnson and Merck highlight BigHat's credibility and the advanced capabilities of its Milliner platform.
Help us improve and share your feedback! Did you find this helpful?